Eli Lilly Gears Up for Donanemab Adcomm as FDA Ponders Changes to Format

[cafead]

via On April 29, the FDA announced it would hold a listening session to discuss the composition of advisory committees and ways to ensure public awareness and understanding of their role in the regulatory process. The news comes as the agency gears up for arguably the biggest advisory committee meeting of the year, regarding Eli Lilly’s highly anticipated Alzheimer’s drug donanemab.

article source